Long-term efficacy and safety of once daily treatment of chronic plaque psoriasis with tacalcitol ointment
Peter C.M. van de Kerkhof, Carine J. M. van der Vleuten, M. Gerritsen, Conrad P. Glade, Thomas Anton Luger, T. Werfel, B. Klüss
Abstract
Peter C.M. van de Kerkhof, Carine J. M. van der Vleuten, M. Gerritsen, Conrad P. Glade, Thomas Anton Luger, T. Werfel, B. Klüss
Abstract
Vitamin D3 analogues represent a major innovation in the treatment of psoriasis today [1-4]. During the last 5 years, calcipotriol (50 µg/g) ointment has become a first line therapy for this condition. Calcipotriol treatment is generally accepted for long-term management of psoriasis, although irritation of the skin has been experienced by 25% of the patients and required discontinuation of treatment in approximately 6% of the [...]
OpenAlex reports 20 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Vitamin D3 analogues represent a major innovation in the treatment of psoriasis today [1-4]. During the last 5 years, calcipotriol (50 µg/g) ointment has become a first line therapy for this condition. Calcipotriol treatment is generally accepted for long-term management of psoriasis, although irritation of the skin has been experienced by 25% of the patients and required discontinuation of treatment in approximately 6% of the [...]
Key concepts: Medicine, Calcipotriol, Psoriasis, Discontinuation, Dermatology, Plaque psoriasis, Irritation, Skin irritation